Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: J Immunol. 2016 Feb 24;196(7):3180–3190. doi: 10.4049/jimmunol.1501435

Figure 4. CD40/CD154 signaling is necessary and sufficient for CD8 T cell recovery following antibody-mediated depletion.

Figure 4

A. B6 recipients of BALB/c heart allografts were treated with mATG with or without anti-CD154 mAb (clone MR1, 1 mg i.v. on day −1). The percentages of CD8+ T cell were evaluated in peripheral blood at indicated time points. Data are presented as mean ±SD, N = 5 mice/group. P values are shown for comparisons between mATG alone (closed circles) versus mATG + anti-CD154 mAb (open circles) treated groups. *P < 0.05; **P < 0.01; ***P < 0.001. B. B6 recipients of BALB/c heart allografts were depleted of CD4 T cells and treated with mATG with or without the injection of agonistic anti-CD40 mAb (clone FKG4.5; 100 μg i.v. on days 0, 1). The percentages of CD8+ T cells in peripheral blood are presented as mean ±SD, N =5-8 mice per group. P values are shown for comparisons between mATG + anti-CD mAb (open circles) versus mATG + anti-CD4 mAb + agonistic anti-CD40 mAb (open diamonds) treated groups. *P < 0.05; **P < 0.01; ***P < 0.001. C. The percentages of CD4+ T cells in peripheral blood of recipients shown in panels A and B are presented as mean ±SD. N = 5-8 mice per group. D. Kaplan-Meier survival curves represent heart allograft survival in recipients depleted of CD4 T cells and treated with mATG with or without the injection of agonistic anti-CD40 mAb. N = 8-11 mice per group.